Learning from the "tsunami" of immune checkpoint inhibitors in 2015

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) represent a significant advancement in cancer therapy.
• The year 2015 witnessed a substantial increase in FDA approvals and research surrounding ICIs.

Purpose of the Study:

• To review new indications for anti-CTLA4 and anti-PD1 therapies approved by the FDA in 2015.
• To summarize positive clinical trial findings and promising abstracts presented at major scientific meetings in 2015.
• To discuss critical aspects of ICI use, including predictive factors, combinations, and management.

Main Methods:

• Comprehensive review of FDA approvals for anti-CTLA4 and anti-PD1 drugs in 2015.
• Analysis of published clinical trials and abstracts from key scientific conferences.
• Discussion of critical issues related to ICI implementation and patient care.

Main Results:

• Multiple new indications for anti-CTLA4 and anti-PD1 immune checkpoint inhibitors were approved by the FDA.
• Numerous clinical trials and scientific abstracts highlighted promising efficacy and outcomes.
• Key areas of discussion included predictive biomarkers, combination strategies, and treatment management.

Conclusions:

• 2015 marked a pivotal year for immune checkpoint inhibitors in oncology.
• Further research and discussion are needed to optimize the use, management, and accessibility of these novel therapies.